|
| |
Paclitaxel protein-bound particles for injectable suspension
Abraxane™
|
|
Indication: |
Metastatic/relapsed breast cancer after failure of other chemotherapy |
|
Pharmacology: |
Antimicrotubule antineoplastic agent |
|
Usual Dose: |
260 mg/m² IV over 30 minutes every 3 weeks |
|
Contraindications: |
Baseline neutrophils <1500 cells/mm³ |
|
Warnings: |
Dose-dependent bone marrow suppression is the dose-limiting toxicity
Monitor blood counts frequently
Do not readminister until neutrophils >1500 cells/mm³ and platelets
>100,000 cells/mm³
Safety unknown in patients with serum bilirubin >1.5 mg/dL or creatinine
>2 mg/dL
Drug contains human albumin - theoretical risk of CJD transmission
Withhold treatment if Grade 3 sensory neuropathy develops and reduce
subsequent doses
Monitor closely for extravasation
Men should not father a child and women should avoid pregnancy during
treatment
Discontinue breastfeeding during treatment
Safety and efficacy not established in pediatric patients
|
|
Pregnancy Category: |
D |
|
Side Effects: |
neutropenia, thrombocytopenia, anemia, infections, febrile neutropenia,
bleeding
hypersensitivity reactions
bradycardia, hypotension, abnormal ECG, chest pain, SVT, thrombosis,
hypertension
pulmonary thromboembolism, pulmonary embolus
cough, dyspnea
sensory neuropathy
myalgia, arthralgia, asthenia
fluid retention, edema
nausea, vomiting, diarrhea, mucositis
alopecia
elevation bilirubin, alkaline phosphatase, AST
injection site reaction |
|
Drug Interactions: |
Theoretically, substrates or inhibitors of CYP450 2C8 and 3A4 |
|
